Get the Stockscreener App
16.61
1.72%
-0.29
Pre-market:
16.69
0.08
+0.48%
Aurinia Pharmaceuticals Inc stock is traded at $16.61, with a volume of 668.21K.
It is down -1.72% in the last 24 hours and down -0.24% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$16.90
Open:
$16.9
24h Volume:
668.21K
Relative Volume:
0.50
Market Cap:
$2.21B
Revenue:
$298.30M
Net Income/Loss:
$298.21M
P/E Ratio:
7.6767
EPS:
2.1637
Net Cash Flow:
$166.93M
1W Performance:
+1.22%
1M Performance:
-0.24%
6M Performance:
+18.47%
1Y Performance:
+27.77%
1-Day Range:
$16.56
$16.91
1-Week Range:
$15.98
$17.16
52-Week Range:
$10.34
$19.25
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
16.61 | 2.14B | 298.30M | 298.21M | 166.93M | 2.1637 |
VRTX
Vertex Pharmaceuticals Inc
|
510.72 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
798.17 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
172.94 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
988.20 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.67 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
GOOGL Stock Price TodayAlphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits
Aurinia Pharmaceuticals Stock Price Forecast. Should You Buy AUPH? - StockInvest.us
Responsive Playbooks and the AUPH Inflection - Stock Traders Daily
LB Pharmaceuticals Names Joseph M. Miller as CFO, Details Compensation and Severance Package - kalkinemedia.com
LB Pharmaceuticals Inc Announces Appointment of Joseph M. Miller to Chief Financial Officer, Effective September 2, 2026 - marketscreener.com
A finance executive who helped launch a lupus drug joins LB Pharmaceuticals - Stock Titan
Is Aurinia Pharmaceuticals (AUPH) Still Below Fair Value After A 60% Rise? - simplywall.st
Kezar Life Sciences stock in focus after Aurinia tender offer and merger terms surface - AD HOC NEWS
AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors - Stocktwits
Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)? - Yahoo Finance
Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock - Benzinga
ILJIN group pushes Aurinia (NASDAQ: AUPH) stake under 5% after share sales - Stock Titan
Aurinia Pharmaceuticals (AUPH) Is Up 8.4% After Teva Agrees To Delay Generic Voclosporin Launch - webull.com
Aurinia (AUPH) Quarterly Results: EPS Clears the Reported Estimate at the Close; Market Response: The Share Price Sheds 0.48% in the Available RecordGuidance Update - vinanet.vn
Aurinia (AUPH) Market: Falls 3.59% to $16.65 at the Close; Technical Setup: $15.82 and $17.48 Define the Nearby Reference Levels on the DayBuyback Factor - siam.in
Aurinia (NASDAQ: AUPH) officer to sell 47,000 shares for taxes - Stock Titan
Teva and Aurinia settle generics dispute over lupus drug, voclosporin - Life Sciences IP Review
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates - Eastern Progress
Zacks Investment ResearchGlobes - Globes - Israel Business News
Aurinia Secures Lupkynis Exclusivity Through 2036 in Teva Patent Settlement - finance.biggo.com
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises - Yahoo Finance UK
Bloom Burton Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21 - Moomoo
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug - Benzinga
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17 - Moomoo
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback - Yahoo Finance
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain - Yahoo Finance
Aurinia Pharmaceuticals and Teva Pharmaceuticals Resolve Patent Litigation Over Generic Voclosporin Capsules - Kalkine Media
AUPH Stock Rallies 6% After-Hours — Here’s Why - Stocktwits
Aurinia Settles Patent Lawsuit With Teva; Shares Rise After Hours - marketscreener.com
Aurinia settles patent dispute with Teva over generic drug By Investing.com - Investing.com Canada
Aurinia stock falls on Teva patent settlement for voclosporin By Investing.com - Investing.com Australia
Aurinia, Teva Reach Voclosporin Patent Litigation Settlement - TipRanks
Aurinia stock falls on Teva patent settlement for voclosporin - Investing.com
Aurinia settles patent dispute with Teva over generic drug - Investing.com
Aurinia Settles Patent Litigation with Teva - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Aurinia (AUPH) Latest Price Review: Rises 0.07% to $15.30 in the Current Update; Level Check: the Near-Term Reference Band Stretches From $14.54 to $16.07 under the Current SnapshotETF Outflow Streak - vinanet.vn
Aurinia (AUPH) Earnings Metrics: EPS Comes in Above Forecast in the Current Update; Trading-Day Reaction: Shares Move 0.07% UpQuarterly Profit Report - vinanet.vn
Will Aurinia’s Reaffirmed 2026 Guidance and Large Buyback Reshape Aurinia Pharmaceuticals' (AUPH) Narrative? - webull.com
(AUPH) Risk Channels and Responsive Allocation - Stock Traders Daily
Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aurinia Pharmaceuticals advances Lupkynis in ph... - Pluang
Aurinia Pharmaceuticals Doubles Down On Its Pipeline (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Navigating Growth in Biotech with a 10% Upside Potential - DirectorsTalk Interviews
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by Wall Street Zen to Buy - MarketBeat
Aurinia Pharmaceuticals (AUPH) Slips 2.29% to $15.76 as Biotech Momentum FadesGrowth ETF - vinanet.vn
Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aurinia Pharmaceuticals Inc Stock (AUPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Robertson Stephen P. | Chief Legal Officer |
Aug 21 '26 |
Sale |
16.97 |
20,975 |
355,946 |
600,787 |
0.05%
1.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):